Newsgather

schedule iii

Stabil7 Meldungen4 QuellenZuletzt aktualisiert: 24.04.2026

Neueste Meldungen

Trump Administration Reclassifies Medical Marijuana From Schedule I to Schedule III
In Entwicklung
Politik·24.04.2026KI-Zusammenfassung

Trump Administration Reclassifies Medical Marijuana From Schedule I to Schedule III

Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III, marking the most significant U.S. cannabis policy shift in 50 years. The change doesn't legalize marijuana federally but grants medical marijuana operators their first federal tax break, eases research barriers, and legitimizes programs in 40 states. The administration also announced a June hearing for broader reclassification.

T
TOI World
US reclassifies certain marijuana products as a less-dangerous drug
NACHRICHT
23.04.2026

US reclassifies certain marijuana products as a less-dangerous drug

The US Department of Justice is reclassifying FDA-approved and state-licensed marijuana as a less dangerous drug, Acting Attorney General Todd Blanche said on Thursday. The announcement does not legalise marijuana across the United States. In a post on X, Blanche said the Justice Department was “immediately rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to ⁠Schedule III”. The department is also initiating an expedited hearing to consider the broader rescheduling...

S
SCMP Economy
DOJ Reclassifies Marijuana from Schedule I to Schedule III
Dringend
Politik·23.04.2026KI-Zusammenfassung

DOJ Reclassifies Marijuana from Schedule I to Schedule III

The US Department of Justice announced Thursday it is reclassifying FDA-approved and state-licensed marijuana from Schedule I to Schedule III, representing one of the most significant federal changes to marijuana policy in decades. Acting Attorney General Todd Blanche said the move removes barriers to researching the drug's safety and efficacy. The decision follows a December executive order from President Donald Trump directing the DOJ to loosen marijuana restrictions, though the rescheduling does not legalize marijuana across the United States.

S
SCMP Economy
Trump Administration Moves to Reclassify Cannabis from Schedule I to Schedule III
In Entwicklung
Politik·23.04.2026KI-Zusammenfassung

Trump Administration Moves to Reclassify Cannabis from Schedule I to Schedule III

The Trump administration announced Thursday the reclassification of cannabis from Schedule I to Schedule III under federal law, marking the most significant federal shift on marijuana policy in decades. The change will immediately move FDA-approved cannabis products and state-regulated medical marijuana to Schedule III, while a June hearing will consider formal reclassification. The move lowers research barriers, exempts cannabis companies from IRS Code Section 280E, and opens banking access.

C
CNBC
Trump Administration Moves to Reclassify Cannabis from Schedule I to Schedule III
In Entwicklung
Politik·23.04.2026KI-Zusammenfassung

Trump Administration Moves to Reclassify Cannabis from Schedule I to Schedule III

The Trump administration announced Thursday that the Department of Justice will reclassify cannabis from Schedule I to Schedule III under federal law, marking the most significant federal shift on marijuana policy in decades. The change would not legalize cannabis at the federal level but would expand scientific research, exempt cannabis companies from IRS Code Section 280E, and open banking access. FDA-approved marijuana products and state-regulated medical marijuana items will move to Schedule III immediately, with a formal reclassification hearing scheduled for June.

C
CNBC
Trump Administration Moves Medical Marijuana From Schedule I to Schedule III
In Entwicklung
Politik·23.04.2026KI-Zusammenfassung

Trump Administration Moves Medical Marijuana From Schedule I to Schedule III

The Trump administration announced Thursday that medical marijuana will be moved from Schedule I to Schedule III, a category shared with Tylenol with codeine and anabolic steroids. Acting Attorney General Todd Blanche said the change allows for research on safety and efficacy, providing patients better care. The rescheduling applies only to FDA-approved and state-regulated medical marijuana products. Cannabis businesses in state medical programs would receive tax relief under Section 280E, and researchers would no longer need Schedule I licenses. The DEA will hold hearings on broader rescheduling on June 29.

N
NPR News